Dr. Baijun Fang 房佰俊
Chief Physician
Department of Hematology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of malignant blood diseases, including myeloma, lymphoma, and leukemia. Research focuses on pathogenesis and targeted therapy for these conditions, as well as stem cell treatments for non-malignant blood disorders.
Dr. Fang is a Chief Physician, Professor, and Deputy Director of the Hematology Department at Henan Cancer Hospital. Holding a medical doctorate, Dr. Fang directs the Myeloma Institute at Henan Cancer Research Institute. Research interests include myeloma, lymphoma, leukemia, and stem cell therapies for blood diseases. Dr. Fang has published 28 SCI papers as first or corresponding author in the past five years.
Professional roles
- Member, Youth Committee, Hematology Branch, Chinese Medical Association
- Member, Experimental Diagnosis Group, Hematology Branch, Chinese Medical Association
- Vice Chair, Henan Blood Disease Professional Committee
- Vice Chair, Stem Cell Professional Committee, Henan Immunology Society
Name order: in Chinese the family name comes first (Fang Baijun). Papers usually list the name as Baijun Fang or Fang B.
Selected publications
70 papers on PubMed matched by name and affiliation; 30 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biomark Res, 2026 (senior author): Ubiquitin signaling in tumor-associated macrophage reprogramming: mechanisms and therapeutic opportunities in cancers. PubMed 42888457
- Blood Adv, 2026 (first author): Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing. PubMed 41385406
- Front Biosci (Landmark Ed), 2025 (senior author): Epirubicin Induces Cell Cycle Arrest in Multiple Myeloma Cells by Downregulating CDC20 Expression. PubMed 41351409
- Br J Haematol, 2025 (senior author): Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies. PubMed 40879107
- Ann Hematol, 2025 (senior author): Tandem autologous hematopoietic stem cell transplantation in multiple myeloma: A historical perspective and current challenges. PubMed 40947450
- World J Surg Oncol, 2025 (senior author): Impact of type 2 and steroid-Induced diabetes mellitus on prognosis in patients with multiple myeloma. PubMed 40886007
- Clin Exp Med, 2025 (senior author): Therapeutic options for extramedullary involvement in multiple myeloma. PubMed 40849366
- Asian J Surg, 2023 (senior author): Efficacy and safety of bortezomib plus dexamethasone in patients with refractory primary immune thrombocytopenia: A single-center study. PubMed 37541902
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion